If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- Precision Medicine Research Project Focuses on Rare Cancerson August 6, 2020 at 6:33 am
TargetCancer Foundation (TCF) has announced the Target Rare Cancer Knowledge (TRACK) study, an initiative that leverages genomic analysis and precision medicine to provide patients and providers with ...
- Notable Launches New Clinical Study With Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistanceon August 6, 2020 at 5:31 am
Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced a new precisio ...
- Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactionson August 6, 2020 at 2:13 am
Multiple studies have found the neutrophil to lymphocyte ratio (NLR) to be associated with adverse breast cancer (BC) prognosis and survival. Very limited data exist on the role of NLR and risk of BC.
- Foundation Medicine teams up with local nonprofit to test precision medicine's impacton August 5, 2020 at 12:22 pm
Cambridge nonprofit TargetCancer Foundation is teaming up with Foundation Medicine to study just how well selecting treatments based on the unique genetic characteristics of different cancers helps ...
- TargetCancer Foundation Announces Rare Cancer Precision Medicine Research Initiativeon August 5, 2020 at 4:41 am
TargetCancer Foundation (TCF) proudly announced today the initiation of the TCF-001 TRACK (Target Rare Cancer Knowledge) Study, an innovative trial th ...
- Bayer says struggling to find patients for precision cancer drug Vitrakvion August 4, 2020 at 11:43 am
Bayer said it is finding it hard to identify cases of the rare tumour types that qualify for treatment with Vitrakvi, a precision cancer drug which it hopes will improve prospects of its drugs ...
- POINT Biopharma Announces Successful USD $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patientson August 4, 2020 at 4:45 am
POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, has completed a USD $20 Million Series A ...
- Europe Precision Medicine Market 2020 Share, Trends, Segmentation and Forecast by 2025on July 31, 2020 at 2:00 am
The 'Precision Medicine Market' research report provides a succinct analysis on the recent market trends. In addition, the report offers a thorough abstract on the statistics, market estimates and ...
- Precision medicine identifies key recurring mutation in head and neck cancerson July 30, 2020 at 10:36 pm
Treatment with tipifarnib ... according to Cancer.Net. More information: Mara Gilardi et al, Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas, Molecular ...
via Bing News